Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$245.44 +6.57 (+2.75%)

(As of 12/20/2024 05:31 PM ET)

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
1

Hold
5

Buy
18

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 5 have given a hold rating, and 18 have given a buy rating for ALNY.

Consensus Price Target

$298.09
21.45% Upside

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $298.09. The highest price target for ALNY is $400.00, while the lowest price target for ALNY is $159.00. The average price target represents a forecasted upside of 21.45% from the current price of $245.44.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

ALNY Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	13 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$298.09	$298.09	$279.14	$227.85
Forecasted Upside	21.45% Upside	21.72% Upside	2.69% Upside	19.28% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.45% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent ALNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
11/18/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$400.00 ➝ $400.00	+72.56%
11/18/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$296.00 ➝ $296.00	+27.70%
11/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform
11/1/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$275.00 ➝ $298.00	+10.74%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$300.00 ➝ $300.00	+11.79%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$295.00 ➝ $329.00	+23.61%
11/1/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$305.00 ➝ $310.00	+16.48%
11/1/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$366.00 ➝ $384.00	+44.04%
11/1/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00	+20.03%
11/1/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+12.53%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$282.00 ➝ $371.00	+25.37%
10/14/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$307.00 ➝ $314.00	+10.70%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $220.00	-21.77%
8/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$248.00 ➝ $280.00	+3.37%
8/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$198.00 ➝ $370.00	+40.85%
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$207.00 ➝ $233.00	-14.17%
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$291.00 ➝ $342.00	+24.91%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$250.00 ➝ $255.00	-3.04%
6/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$253.00 ➝ $288.00	+18.37%
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$215.00 ➝ $295.00	+20.32%
6/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$138.00 ➝ $159.00	-33.15%
6/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$210.00 ➝ $260.00	+12.40%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$234.00 ➝ $234.00	+3.28%
10/11/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$237.00 ➝ $218.00	+28.97%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$220.00	+8.83%
2/21/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$304.00	+48.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:40 AM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 11, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

Alnylam Pharmaceuticals, Inc. has a strong market capitalization of $33.05 billion, indicating a robust position in the biopharmaceutical sector, which can provide stability and growth potential for investors.
The company focuses on innovative therapeutics based on ribonucleic acid interference, a cutting-edge area in medicine that could lead to significant advancements in treatment options and market opportunities.
Despite recent earnings challenges, the stock price has shown resilience, currently trading around $250.98, which may present a buying opportunity for investors looking for growth in the biopharmaceutical space.
Institutional investors hold a significant 92.97% of the company's stock, suggesting strong confidence from large financial entities in Alnylam Pharmaceuticals, Inc.'s future performance.
Recent insider trading activity, including sales by executives, may indicate a strategic repositioning within the company, which could lead to future growth and value creation.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The company reported a significant earnings miss with an EPS of ($0.87), falling short of the consensus estimate of ($0.51), which raises concerns about its profitability and operational efficiency.
Quarterly revenue decreased by 33.3% year-over-year, indicating potential challenges in maintaining sales momentum and market share, which could impact future growth prospects.
Analysts forecast a negative EPS of -2.21 for the current year, suggesting ongoing financial difficulties that may deter potential investors.
The stock has a high P/E ratio of -96.11, reflecting a lack of profitability and potentially overvalued stock price, which could pose risks for investors seeking value.
Insider sales, while sometimes viewed positively, can also signal a lack of confidence in the company's short-term performance, which may concern potential investors.

ALNY Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $298.09, with a high forecast of $400.00 and a low forecast of $159.00.
: 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 5 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.
: According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 21.45% based on their 12-month stock forecasts.
: Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 downgrade by analysts.
: Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, Scotiabank, TD Cowen, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.71 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Collect $7k per month from Tesla’s SECRET dividend (Ad)

Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…

Click here to discover the new #1 way to invest in Tesla

This page (NASDAQ:ALNY) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target